SCHEMBL6315528

SCHEMBL6315528

Cc1ccc(-c2noc(N)c2C(=O)NC2CCCc3ccccc32)s1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 8/20 0.60
TAS1R1 Q7RTX1 8/20 0.60
RECQL P46063 1/20 0.60
TSHR P16473 1/20 0.56
TAS1R2 Q8TE23 7/20 0.55
CNR1 P21554 3/20 0.52
CNR2 P34972 2/20 0.52
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 2/20 0.50
HTT P42858 1/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323197 0.94 TAS1R3 (0.52) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6317145 0.90 RECQL (0.55) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6317746 0.90 RECQL (0.54) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6318358 0.90 TAS1R3 (0.54) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6315002 0.84 RECQL (0.47) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6317555 0.84 CA1 (0.50) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6316018 0.84 RECQL (0.46) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6315937 0.83 RECQL (0.58) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6317860 0.83 ALDH1A1 (0.60) TAS1R3TAS1R1RECQLTSHRTAS1R2
SCHEMBL6317293 0.81 RECQL (0.59) TAS1R3TAS1R1RECQLTSHRTAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 TAS1R3 4289/4885TAS1R1 4258/4885RECQL 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.